India’s Pharmaceutical Sector Enters a New Growth Phase Through Affordable Medicines and Self-Reliance

India’s pharmaceutical sector has recorded strong growth over the past twelve years, supported by policy reforms, affordable healthcare programmes and a sustained push for domestic manufacturing. The country’s pharma industry is now being shaped by two major national priorities: making essential medicines affordable for citizens and reducing dependence on imported raw materials, formulations and high-value pharmaceutical inputs.

A key pillar of this transformation is the expansion of the Pradhan Mantri Bhartiya Janaushadhi Pariyojana. The number of Jan Aushadhi Kendras has increased from around 84 centres in 2014 to more than 19,200 centres across the country in 2026. This expansion has taken low-cost, quality generic medicines closer to ordinary families, especially in smaller towns, semi-urban areas and rural districts. The programme has also helped citizens save more than ₹40,000 crore on healthcare expenses.

This is an important healthcare shift because medicine costs form a major part of household medical spending. For many families, long-term treatment for diabetes, blood pressure, heart disease, respiratory illness or pain management can become a recurring financial burden. Jan Aushadhi Kendras reduce this pressure by offering quality generic alternatives at affordable prices. The result is wider access, lower out-of-pocket expenditure and stronger public trust in generic medicines.

The Production Linked Incentive Scheme for Pharmaceuticals has attracted cumulative investments of more than ₹42,600 crore. It has generated sales worth over ₹3.43 lakh crore and created employment for more than 1.13 lakh people. These numbers show that the sector is moving beyond distribution and affordability into deeper industrial capacity building.

The manufacturing push is especially important for India’s long-term health security. During global supply disruptions, countries with strong domestic pharmaceutical production are better placed to protect their citizens. India already has a global reputation as the “Pharmacy of the World” because of its role in supplying affordable medicines and vaccines. The current policy direction strengthens that position by encouraging local production, investment, jobs and supply-chain resilience.

Active pharmaceutical ingredients, key starting materials and high-end formulations are essential to national preparedness. When domestic capacity expands in these areas, India gains more control over medicine availability, pricing stability and emergency response. This becomes crucial during pandemics, geopolitical disruptions or sudden spikes in demand for critical drugs.

The growth of the sector also supports employment across several layers. Large pharmaceutical companies create jobs in research, manufacturing, quality control, packaging, logistics and exports. Jan Aushadhi Kendras create local entrepreneurship opportunities and pharmacy-linked employment. Allied sectors such as chemicals, laboratory equipment, cold-chain logistics, medical distribution and regulatory services also benefit from pharma expansion.

India’s pharmaceutical rise also links directly with exports. Indian medicines are used across developing and developed markets because they combine scale, affordability and regulatory capability. As manufacturing investments grow, India can move further into complex generics, biosimilars, speciality medicines, vaccines and high-value formulations. This will help the country retain its strength in affordable medicine while climbing the value chain.

India’s pharma sector is becoming both a public-health asset and an industrial-growth engine. Affordable generic medicines are reducing the cost burden on citizens, while production incentives are strengthening domestic manufacturing. Together, these reforms support healthcare access, employment, exports and Atmanirbhar Bharat.